Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes

R. Martino, A. Henseler, M. van Lint, N. Schaap, J. Finke, D. Beelen, S. Vigouroux, EP. Alessandrino, GJ. Mufti, JH. Veelken, B. Bruno, I. Yakoub-Agha, L. Volin, J. Maertens, R. Or, V. Leblond, M. Rovira, P. Kalhs, AF. Alvarez, A. Vitek, J....

. 2017 ; 52 (8) : 1107-1112. [pub] 20170320

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc18025121
E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Freely Accessible Science Journals from 1997 to 1 year ago
ProQuest Central from 1997-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago

Links

PubMed 28319072
DOI 10.1038/bmt.2017.19
Knihovny.cz E-resources

This study shows the long-term updated outcomes of a multicenter retrospective study which analyzed 843 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor with either reduced-intensity conditioning (RIC) in 213 patients, or standard myeloablative conditioning (MAC) in 630 patients. In multivariate analysis, the 13-year relapse rate was significantly increased after RIC (31% after MAC vs 48% in RIC; HR, 1.5; 95% CI, 1.1-1.9; P=0.04), but with no differences in overall survival (OS) (30% after MAC vs 27% in RIC; P=0.4) and PFS (29 vs 21%, respectively, P=0.3). Non-relapse mortality was higher in MAC (40 vs 31%; P=0.1), especially in patients older than 50 years (50 vs 33%, P<0.01). In addition, long-term follow-up confirms the importance of other variables on 13-year OS, mainly MDS risk category, disease phase, cytogenetics and receiving a high donor cell dose, irrespective of the conditioning regimen used.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025121
003      
CZ-PrNML
005      
20180711100038.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bmt.2017.19 $2 doi
035    __
$a (PubMed)28319072
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Martino, R $u Hospital Santa Creu i Sant Pau, Barcelona, Spain.
245    10
$a Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes / $c R. Martino, A. Henseler, M. van Lint, N. Schaap, J. Finke, D. Beelen, S. Vigouroux, EP. Alessandrino, GJ. Mufti, JH. Veelken, B. Bruno, I. Yakoub-Agha, L. Volin, J. Maertens, R. Or, V. Leblond, M. Rovira, P. Kalhs, AF. Alvarez, A. Vitek, J. Sierra, E. Wagner, M. Robin, T. de Witte, N. Kröger,
520    9_
$a This study shows the long-term updated outcomes of a multicenter retrospective study which analyzed 843 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor with either reduced-intensity conditioning (RIC) in 213 patients, or standard myeloablative conditioning (MAC) in 630 patients. In multivariate analysis, the 13-year relapse rate was significantly increased after RIC (31% after MAC vs 48% in RIC; HR, 1.5; 95% CI, 1.1-1.9; P=0.04), but with no differences in overall survival (OS) (30% after MAC vs 27% in RIC; P=0.4) and PFS (29 vs 21%, respectively, P=0.3). Non-relapse mortality was higher in MAC (40 vs 31%; P=0.1), especially in patients older than 50 years (50 vs 33%, P<0.01). In addition, long-term follow-up confirms the importance of other variables on 13-year OS, mainly MDS risk category, disease phase, cytogenetics and receiving a high donor cell dose, irrespective of the conditioning regimen used.
650    _2
$a senioři $7 D000368
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a následné studie $7 D005500
650    _2
$a testování histokompatibility $7 D006650
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myelodysplastické syndromy $x mortalita $x terapie $7 D009190
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sourozenci $7 D035781
650    _2
$a analýza přežití $7 D016019
650    _2
$a dárci tkání $7 D014019
650    _2
$a příprava pacienta k transplantaci $x metody $x mortalita $7 D019172
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Henseler, A $u EBMT Data Office, Leiden, The Netherlands.
700    1_
$a van Lint, M $u Ospedale San Martino, Genova, Italy.
700    1_
$a Schaap, N $u Radboud University-Nijmegen Medical Center, Nijmegen, The Netherlands.
700    1_
$a Finke, J $u University of Freiburg, Freiburg, Germany.
700    1_
$a Beelen, D $u University Hospital, Essen, Germany.
700    1_
$a Vigouroux, S $u Hôpital Haut-Leveque, Pessac, France.
700    1_
$a Alessandrino, E P $u Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
700    1_
$a Mufti, G J $u GKT School of Medicine, London, UK.
700    1_
$a Veelken, J H $u Leiden University Hospital, Leiden, The Netherlands.
700    1_
$a Bruno, B $u A.O.U Citta della Salute e della Scienza di Torino, Torino, Italy.
700    1_
$a Yakoub-Agha, I $u CHU de Lille, CIRIC INSERM U995, Université de Lille 2, Lille, France.
700    1_
$a Volin, L $u HUCH Comprehensive Cancer Center, Helsinki, Finland.
700    1_
$a Maertens, J $u University Hospital Gasthuisberg, Leuven, Belgium.
700    1_
$a Or, R $u Hadassah University Hospital, Jerusalem, Israel.
700    1_
$a Leblond, V $u Universite Paris IV, Hopital la Pitié-Salpêtrière, Paris, France.
700    1_
$a Rovira, M $u Hospital Clinic, Barcelona, Spain.
700    1_
$a Kalhs, P $u Medizinische Universitaet Wien, Vienna, Austria.
700    1_
$a Alvarez, A F $u Hospital de la Princesa, Madrid, Spain.
700    1_
$a Vitek, A $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Sierra, J $u Hospital Santa Creu i Sant Pau, Barcelona, Spain.
700    1_
$a Wagner, E $u University Medical Center Mainz, Mainz, Germany.
700    1_
$a Robin, M $u Hopital St. Louis, Paris, France.
700    1_
$a de Witte, T $u Radboud University-Nijmegen Medical Center, Nijmegen, The Netherlands.
700    1_
$a Kröger, N $u University Hospital Eppendorf, Hamburg, Germany.
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 52, č. 8 (2017), s. 1107-1112
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28319072 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180711100329 $b ABA008
999    __
$a ok $b bmc $g 1317252 $s 1022042
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 52 $c 8 $d 1107-1112 $e 20170320 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20180709
Back

Find record

Citation metrics

Archiving options